Physician profile
Saeed Bidar
NPI 1629041678
$2,323.27
in general payments reported to CMS, 2019-2025
14 companies · $22.70 in 2025
The $22.70 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $125 · 2021: $423 · 2022: $446 · 2023: $574 · 2024: $404 · 2025: $22.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978 · Education: $22.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.68 |
| Education | $22.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $603.66 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $318.78 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $207.79 | 2022-2023 | Lokelma |
| Janssen Pharmaceuticals, INC | $195.86 | 2019-2021 | |
| Outset Medical INC | $178.66 | 2024 | |
| Calliditas Therapeutics US INC. | $170.64 | 2024 | |
| Abbott Laboratories | $159.79 | 2021-2024 | Cardiomems |
| Aurinia Pharma U.S., INC. | $148.96 | 2021-2023 | Lupkynis |
| Baxter Healthcare | $125.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $121.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $31.33 | 2021-2022 | |
| Travere Therapeutics, INC. | $22.70 | 2025 | Filspari |
| Novo Nordisk INC | $19.45 | 2024 | Ozempic |
| Glaxosmithkline, LLC. | $18.78 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeed Bidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.